Showing 91-100 of 1328 results for "".
- Two New Grants Continue Dr. Fredric S. Brandt's Legacyhttps://practicaldermatology.com/news/two-new-grants-continue-dr-fredric-s-brandts-legacy/2458018/Two American Society for Dermatologic Surgery members received grants totaling more tha
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- #RealDealAesthetics Takes on Minimally Invasive Body Contouringhttps://practicaldermatology.com/news/realdealaesthetics-takes-on-minimally-invasive-body-contouring/2459934/Save the date: Practical Dermatology®'s sister publication Modern Aesthetics’ newest Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD is back. The f
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Advanced Aesthetic Technologies, Inc.’s Algeness Named Top Finalist in Terra2 Solution Skin Health Innovation Competitionhttps://practicaldermatology.com/news/advanced-aesthetic-technologies-incs-algeness-named-top-finalist-in-terra2-solution-skin-health-innovation-competition/2460708/Advanced Aesthetic Technologies, Inc. (AAT) and Algeness are finalists in the recent Terra2 Solutions Skin Health Innovation Competition. Algeness is a patented family of fully resorbable injectable gel implant dermal fillers that are 100% natural and based on purified agarose with
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as